Literature DB >> 1320320

Recurrent herpes zoster myelitis treated with human interferon alpha: a case report.

T Nakano1, E Awaki, S Araga, H Takai, K Inoue, K Takahashi.   

Abstract

Recurrent herpes zoster myelitis is very rare. However, a case was recently observed in our hospital. A 43-year-old woman developed myelitis 2 weeks after development of shingles. Her condition was improved by methylprednisolone. Seven months later, she developed myelitis after development of shingles again. Antibody against varicella-zoster (VZV), increased in the serum, but was negative in the cerebrospinal fluid. Methylprednisolone was not sufficiently effective against this attack. The refractory sensory disturbance was improved by human interferon alpha (IFN-alpha). Natural killer cell activity, the helper T-cell/suppressor T-cell ratio and the kappa/lambda ratio of B-cells increased with clinical improvement. In this case, delayed-type hypersensitivity after VZV infection played a role in the occurrence of myelopathy and clinical improvement resulted from the immunosuppressive effects of IFN-alpha.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1320320     DOI: 10.1111/j.1600-0404.1992.tb04064.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  3 in total

1.  Recurrent varicella zoster virus myelopathy.

Authors:  Don Gilden; Maria A Nagel; Richard M Ransohoff; Randall J Cohrs; Ravi Mahalingam; Jody L Tanabe
Journal:  J Neurol Sci       Date:  2008-10-21       Impact factor: 3.181

Review 2.  Recognition and treatment of shingles.

Authors:  A F Nikkels; G E Piérard
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

3.  Myelitis: A Rare Neurological Complication of Herpes Zoster.

Authors:  Monika Mohanbhai Agrawal; Rashmi Samir Mahajan; Freny Erachshaw Bilimoria; Kishan Rasubhai Ninama
Journal:  Indian J Dermatol       Date:  2016 Nov-Dec       Impact factor: 1.494

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.